What is the 13F Pro Quality Score for CLRB?

13F Pro ranks Cellectar Biosciences, Inc. (CLRB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLRB's current score at https://13fpro.ai/research/CLRB (free sign-up required for the full ranking).

Where does 13F Pro source CLRB data?

All Cellectar Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cellectar Biosciences, Inc. files with the SEC under CIK 1279704. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLRB in?

Cellectar Biosciences, Inc. (CLRB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLRB research updated on 13F Pro?

CLRB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cellectar Biosciences, Inc.(CLRB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1279704 CLRB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CLRB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cellectar Biosciences, Inc. (CLRB), a Healthcare sector company. CLRB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Cellectar Biosciences, Inc. reports net income of $-5.7M, free cash flow of $-4.8M. Top institutional holders of CLRB by reported 13-F value include Bleichroeder, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. CLRB trades on the Nasdaq exchange and files with the SEC under CIK 1279704. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLRB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cellectar Biosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.7M

Free Cash Flow

Q1 2026

$-4.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+51.1% YoY

$-21.8MFY 2025

FY20 $-15.1MFY23 $-42.8MFY24 $-44.6MFY25 $-21.8M

Operating Income

+55.6% YoY

$-23.0MFY 2025

FY20 $-15.3MFY23 $-39.0MFY24 $-51.8MFY25 $-23.0M

EPS (Diluted)

+80.1% YoY

$-8.35FY 2025

FY20 $-0.09FY23 $-3.50FY24 $-41.89FY25 $-8.35

Total Assets

-41.2% YoY

$15.0MFY 2025

FY20 $58.7MFY23 $12.1MFY24 $25.5MFY25 $15.0M

Op. Cash Flow

+51.4% YoY

$-23.1MFY 2025

FY20 $-13.9MFY23 $-32.4MFY24 $-47.6MFY25 $-23.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2019	FY 2018
Net Income	$-21.8M +51.1%	$-44.6M -4.2%	$-42.8M -183.4%	$-15.1M -7.1%	$-14.1M -6.4%	$-13.2M
Operating Income	$-23.0M +55.6%	$-51.8M -32.9%	$-39.0M -154.8%	$-15.3M -7.8%	$-14.2M -6.4%	$-13.3M
EPS (Diluted)	$-8.35 +80.1%	$-41.89 -1096.9%	$-3.50 -3704.3%	$-0.09	—	—
Total Assets	$15.0M -41.2%	$25.5M +111.0%	$12.1M -79.4%	$58.7M +378.8%	$12.3M -18.6%	$15.1M
Operating Cash Flow	$-23.1M +51.4%	$-47.6M -47.0%	$-32.4M -132.4%	$-13.9M -19.1%	$-11.7M -2.2%	$-11.4M

AI Insight: CLRB Financial Trends

Cash burn stabilized at ~$5M quarterly, but equity base eroded 75% from Q2 2024 to Q1 2026, signaling mounting solvency risk.

• Operating losses narrowed from $14M (Q2 2024) to $5–6M (Q3 2025–Q1 2026), a 57–64% improvement.

• Operating cash burn declined from $14M (Q2 2024) to $4–5M (Q3 2025–Q1 2026), showing better cash discipline.

• Shareholder equity collapsed from $12–15M (Q2–Q3 2024) to $3M (Q1 2026), indicating material dilution or losses.

⚠ Equity at $3M in Q1 2026 — critically low; any further losses threaten balance-sheet solvency within quarters.

⚠ No revenue reported across all quarters; company remains pre-commercial or severely undisclosed on product traction.

AI Insight: CLRB Ratio Trends

Insufficient financial data to assess trends; only two quarters show measurable returns, both deeply negative.

• ROA deteriorated sharply from -12.5% in Q2 2024 to -37.0% in Q4 2024, signaling worsening asset productivity.

• ROE declined from -29.7% in Q2 2024 to -65.9% in Q4 2024, reflecting mounting losses relative to shareholder equity.

⚠ All profitability and efficiency metrics absent from Q1 2025 through Q1 2026; lack of visibility hampers assessment of turnaround progress.

⚠ No debt/equity ratios reported; cannot evaluate leverage trajectory or balance sheet health.

Get alerted when CLRB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cellectar Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLRB

Bleichroeder LP
$254.0K100,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$208.0K81,884 sh
GEODE CAPITAL MANAGEMENT, LLC
$134.1K52,778 sh
Riverview Capital Advisers, LLC
$50.1K10,384 sh
Sequoia Financial Advisors, LLC
$47.9K18,850 sh
VANGUARD FIDUCIARY TRUST CO
$42.1K16,573 sh
Warberg Asset Management LLC
$35.3K13,900 sh
UBS Group AG
$24.5K9,647 sh
BlackRock, Inc.
$12.1K4,745 sh
Tower Research Capital LLC (TRC)
$2.0K793 sh

Fund	Value	Shares
Bleichroeder LP	$254.0K	100,000
VANGUARD CAPITAL MANAGEMENT LLC	$208.0K	81,884
GEODE CAPITAL MANAGEMENT, LLC	$134.1K	52,778
Riverview Capital Advisers, LLC	$50.1K	10,384
Sequoia Financial Advisors, LLC	$47.9K	18,850
VANGUARD FIDUCIARY TRUST CO	$42.1K	16,573
Warberg Asset Management LLC	$35.3K	13,900
UBS Group AG	$24.5K	9,647
BlackRock, Inc.	$12.1K	4,745
Tower Research Capital LLC (TRC)	$2.0K	793

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLRB on your watchlist

Track score changes the day Cellectar Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLRB a good stock to buy?

13F Pro's AI-powered analysis of Cellectar Biosciences, Inc. (CLRB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLRB are available on the CLRB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CLRB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLRB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cellectar Biosciences, Inc.'s investment landscape.